Literature DB >> 20665025

Surveillance of systemic autoimmune rheumatic diseases using administrative data.

S Bernatsky1, L Lix, J G Hanly, M Hudson, E Badley, C Peschken, C A Pineau, A E Clarke, P R Fortin, M Smith, P Bélisle, C Lagace, L Bergeron, L Joseph.   

Abstract

There is growing interest in developing tools and methods for the surveillance of chronic rheumatic diseases, using existing resources such as administrative health databases. To illustrate how this might work, we used population-based administrative data to estimate and compare the prevalence of systemic autoimmune rheumatic diseases (SARDs) across three Canadian provinces, assessing for regional differences and the effects of demographic factors. Cases of SARDs (systemic lupus erythematosus, scleroderma, primary Sjogren's, polymyositis/dermatomyositis) were ascertained from provincial physician billing and hospitalization data. We combined information from three case definitions, using hierarchical Bayesian latent class regression models that account for the imperfect nature of each case definition. Using methods that account for the imperfect nature of both billing and hospitalization databases, we estimated the over-all prevalence of SARDs to be approximately 2-3 cases per 1,000 residents. Stratified prevalence estimates suggested similar demographic trends across provinces (i.e. greater prevalence in females-versus-males, and in persons of older age). The prevalence in older females approached or exceeded 1 in 100, which may reflect the high burden of primary Sjogren's syndrome in this group. Adjusting for demographics, there was a greater prevalence in urban-versus-rural settings. In our work, prevalence estimates had good face validity and provided useful information about potential regional and demographic variations. Our results suggest that surveillance of some rheumatic diseases using administrative data may indeed be feasible. Our work highlights the usefulness of using multiple data sources, adjusting for the error in each.

Entities:  

Mesh:

Year:  2010        PMID: 20665025     DOI: 10.1007/s00296-010-1591-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  22 in total

1.  Bayesian approaches to modeling the conditional dependence between multiple diagnostic tests.

Authors:  N Dendukuri; L Joseph
Journal:  Biometrics       Date:  2001-03       Impact factor: 2.571

2.  The epidemiology of inflammatory bowel disease in Canada: a population-based study.

Authors:  Charles N Bernstein; Andre Wajda; Lawrence W Svenson; Adrian MacKenzie; Mieke Koehoorn; Maureen Jackson; Richard Fedorak; David Israel; James F Blanchard
Journal:  Am J Gastroenterol       Date:  2006-07       Impact factor: 10.864

3.  Robustness of prevalence estimates derived from misclassified data from administrative databases.

Authors:  Martin Ladouceur; Elham Rahme; Christian A Pineau; Lawrence Joseph
Journal:  Biometrics       Date:  2007-03       Impact factor: 2.571

4.  Manpower in Canadian academic rheumatology units: current status and future trends. Canadian Council of Academic Rheumatologists.

Authors:  J G Hanly
Journal:  J Rheumatol       Date:  2001-09       Impact factor: 4.666

5.  The effect of conditional dependence on the evaluation of diagnostic tests.

Authors:  P M Vacek
Journal:  Biometrics       Date:  1985-12       Impact factor: 2.571

6.  The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs.

Authors:  Pantelis Panopalis; Michelle Petri; Susan Manzi; David A Isenberg; Caroline Gordon; Jean-Luc Senécal; John R Penrod; Lawrence Joseph; Yvan St Pierre; Christian Pineau; Paul R Fortin; Nurhan Sutcliffe; Jean-Richard Goulet; Denis Choquette; Tamara Grodzicky; John M Esdaile; Ann E Clarke
Journal:  Arthritis Rheum       Date:  2007-02-15

7.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

Authors:  Charles G Helmick; David T Felson; Reva C Lawrence; Sherine Gabriel; Rosemarie Hirsch; C Kent Kwoh; Matthew H Liang; Hilal Maradit Kremers; Maureen D Mayes; Peter A Merkel; Stanley R Pillemer; John D Reveille; John H Stone
Journal:  Arthritis Rheum       Date:  2008-01

8.  SLE patients with renal damage incur higher health care costs.

Authors:  A E Clarke; P Panopalis; M Petri; S Manzi; D A Isenberg; C Gordon; J-L Senécal; L Joseph; Y St Pierre; T Li
Journal:  Rheumatology (Oxford)       Date:  2008-01-30       Impact factor: 7.580

9.  Validation of diagnostic codes within medical services claims.

Authors:  Machelle Wilchesky; Robyn M Tamblyn; Allen Huang
Journal:  J Clin Epidemiol       Date:  2004-02       Impact factor: 6.437

10.  The cost of systemic sclerosis.

Authors:  Sasha Bernatsky; Marie Hudson; Pantelis Panopalis; Ann E Clarke; Janet Pope; Sharon Leclercq; Yvan St Pierre; Murray Baron
Journal:  Arthritis Rheum       Date:  2009-01-15
View more
  19 in total

1.  The prevalence of systemic autoimmune rheumatic diseases in Canadian pediatric populations: administrative database estimates.

Authors:  Natalie Jane Shiff; Lisa M Lix; Lawrence Joseph; Ciaran Duffy; Lori B Tucker; Lawrence W Svenson; Patrick Belisle; Sasha Bernatsky
Journal:  Rheumatol Int       Date:  2014-09-26       Impact factor: 2.631

2.  The incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia Lupus Registry.

Authors:  S Sam Lim; A Rana Bayakly; Charles G Helmick; Caroline Gordon; Kirk A Easley; Cristina Drenkard
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

3.  Temporal trends in prevalence, incidence, and mortality for rheumatoid arthritis in Quebec, Canada: a population-based study.

Authors:  Sonia Jean; Marie Hudson; Philippe Gamache; Louis Bessette; Paul R Fortin; Gilles Boire; Sasha Bernatsky
Journal:  Clin Rheumatol       Date:  2017-08-21       Impact factor: 2.980

4.  Estimating disease prevalence and incidence using administrative data: some assembly required.

Authors:  Michael M Ward
Journal:  J Rheumatol       Date:  2013-08       Impact factor: 4.666

5.  Receipt of glucocorticoid monotherapy among Medicare beneficiaries with rheumatoid arthritis.

Authors:  Jinoos Yazdany; Chris Tonner; Gabriela Schmajuk; Grace A Lin; Amal N Trivedi
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-10       Impact factor: 4.794

6.  The SPOR-Canadian Data Platform: a national initiative to facilitate data rich multi-jurisdictional research.

Authors:  Lindsey Todd Dahl; Alan Katz; Kimberlyn McGrail; Brent Diverty; Jean-Francois Ethier; Frank Gavin; James Ted McDonald; P Alison Paprica; Michael Schull; Jennifer D Walker; Juliana Wu
Journal:  Int J Popul Data Sci       Date:  2020-11-09

7.  Direct health system costs for systemic lupus erythematosus patients in Alberta, Canada.

Authors:  Francis Fatoye; Tadesse Gebrye; Lawrence W Svenson
Journal:  PLoS One       Date:  2021-05-07       Impact factor: 3.240

8.  Fool's gold: Why imperfect reference tests are undermining the evaluation of novel diagnostics: a reevaluation of 5 diagnostic tests for leptospirosis.

Authors:  Direk Limmathurotsakul; Elizabeth L Turner; Vanaporn Wuthiekanun; Janjira Thaipadungpanit; Yupin Suputtamongkol; Wirongrong Chierakul; Lee D Smythe; Nicholas P J Day; Ben Cooper; Sharon J Peacock
Journal:  Clin Infect Dis       Date:  2012-04-20       Impact factor: 9.079

9.  Bayesian estimation of the accuracy of ICD-9-CM- and CPT-4-based algorithms to identify cholecystectomy procedures in administrative data without a reference standard.

Authors:  S Reza Jafarzadeh; David K Warren; Katelin B Nickel; Anna E Wallace; Victoria J Fraser; Margaret A Olsen
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-09-09       Impact factor: 2.890

10.  Estimating the true accuracy of diagnostic tests for dengue infection using bayesian latent class models.

Authors:  Wirichada Pan-ngum; Stuart D Blacksell; Yoel Lubell; Sasithon Pukrittayakamee; Mark S Bailey; H Janaka de Silva; David G Lalloo; Nicholas P J Day; Lisa J White; Direk Limmathurotsakul
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.